Literature DB >> 20016455

Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis.

F Clerici1, A Del Sole, A Chiti, L Maggiore, M Lecchi, S Pomati, L Mosconi, G Lucignani, C Mariani.   

Abstract

AIM: The aim of this study was to assess whether 18F-fluorodeoxyglucose positron emission tomography differentiates amnestic (aMCI) from single-non-amnestic mild cognitive impairment (snaMCI) with executive dysfunction.
METHODS: Sixteen aMCI subjects (62% females, age 75+/-8 years) and 14 snaMCI subjects (71% females, age 74+/-6 years) underwent [18F]FDG-PET and clinical follow-up. Comparisons between MCI subgroups and with seven cognitively normal elderly subjects were performed using SPM2.
RESULTS: At baseline aMCI and snaMCI exhibited a similar pattern of hypometabolism, mostly in the posterior cingulate gyrus, as compared with controls. In the comparison between the MCI subtypes, the aMCI subjects showed reduced metabolism in the medial temporal lobes (MTL) (hippocampus, fusiform gyrus and amygdala). At follow-up 12 aMCI developed Alzheimer's disease (AD), while snaMCI had a heterogeneous course, including five subjects who developed Lewy body dementia.
CONCLUSIONS: The patterns of altered brain metabolism in aMCI and snaMCI subjects compared to controls are similar and do not provide evidence for making clinical distinctions between them. Comparison between the two MCI subtypes showed MTL hypometabolism in aMCI subjects, possibly reflecting the fact that most had prodromal AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016455

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  17 in total

Review 1.  FDG-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough?

Authors:  Giovanni Lucignani; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

2.  Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates.

Authors:  Ranjan Duara; David A Loewenstein; Maria T Greig; Elizabeth Potter; Warren Barker; Ashok Raj; John Schinka; Amy Borenstein; Michael Schoenberg; Yougui Wu; Jessica Banko; Huntington Potter
Journal:  Am J Geriatr Psychiatry       Date:  2011-11       Impact factor: 4.105

Review 3.  Clinical utility of FDG-PET for the clinical diagnosis in MCI.

Authors:  Javier Arbizu; Cristina Festari; Daniele Altomare; Zuzana Walker; Femke Bouwman; Jasmine Rivolta; Stefania Orini; Henryk Barthel; Federica Agosta; Alexander Drzezga; Peter Nestor; Marina Boccardi; Giovanni Battista Frisoni; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-27       Impact factor: 9.236

Review 4.  A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.

Authors:  Silvia Morbelli; Valentina Garibotto; Elsmarieke Van De Giessen; Javier Arbizu; Gaël Chételat; Alexander Drezgza; Swen Hesse; Adriaan A Lammertsma; Ian Law; Sabina Pappata'; Pierre Payoux; Marco Pagani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09       Impact factor: 9.236

Review 5.  Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.

Authors:  A Del Sole; S Malaspina; Alberto Magenta Biasina
Journal:  Funct Neurol       Date:  2016 Oct/Dec

6.  Assessment of dementia risk in aging adults using both FDG-PET and FDDNP-PET imaging.

Authors:  L M Ercoli; G W Small; P Siddarth; V Kepe; S-C Huang; K J Miller; H Lavretsky; S Y Bookheimer; J R Barrio; D H S Silverman
Journal:  Int J Geriatr Psychiatry       Date:  2012-03-01       Impact factor: 3.485

Review 7.  Should mild cognitive impairment be subtyped?

Authors:  Tiffany F Hughes; Beth E Snitz; Mary Ganguli
Journal:  Curr Opin Psychiatry       Date:  2011-05       Impact factor: 4.741

Review 8.  ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Nadja Smailagic; Marco Vacante; Chris Hyde; Steven Martin; Obioha Ukoumunne; Christos Sachpekidis
Journal:  Cochrane Database Syst Rev       Date:  2015-01-28

9.  Added value of semiquantitative analysis of brain FDG-PET for the differentiation between MCI-Lewy bodies and MCI due to Alzheimer's disease.

Authors:  Federico Massa; Andrea Chincarini; Matteo Bauckneht; Stefano Raffa; Enrico Peira; Dario Arnaldi; Matteo Pardini; Marco Pagani; Beatrice Orso; Maria Isabella Donegani; Andrea Brugnolo; Erica Biassoni; Pietro Mattioli; Nicola Girtler; Ugo Paolo Guerra; Silvia Morbelli; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

Review 10.  Why pleiotropic interventions are needed for Alzheimer's disease.

Authors:  Sally A Frautschy; Greg M Cole
Journal:  Mol Neurobiol       Date:  2010-05-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.